Source - SMW
Scancell Holdings said it continued to collect positive results from patient trials for a cancer treatment.

Overall, 18 of 20 stage III/IV melanoma patients with resected disease remained alive, the company said.

Of the 16 resected patients who received 2-4 mg doses of the treatment, called SCIB1, only six experienced a recurrence of their disease, with only two deaths.

'The continuing survival of these patients is impressive as many had undergone multiple resections of their tumours prior to SCIB1 treatment but have had no evidence of any further disease recurrence,' chief executive Cliff Holloway said.

'This compares extremely favourably with checkpoint inhibitors, but has the advantage of being associated with significantly less toxicity. '

'We remain on track to submit an IND to enable our Phase 2 study combining SCIB1 with a checkpoint inhibitor to start in the second half of this year.'

At 9:45am: (LON:SCLP) Scancell Holdings PLC share price was +0.3p at 13.5p